Gufic Biosciences Ltd
Gufic Biosciences Ltd (GUFICBIO) last reported results for the quarter ended Jun 2026, with sales of ₹261 crore and net profit of ₹22 crore. The stock last traded at ₹406, a market capitalisation of ₹4,080 crore, on a P/E of 55.6. Over the past 52 weeks the stock has ranged between ₹268 and ₹468. Figures are as of 9 Oct 2026 and are not real time.
Gufic Biosciences Ltd share price and key metrics
- Current price
- ₹406
- Market cap
- ₹4,080 cr
- Stock P/E
- 55.6
- Book value
- ₹66.3
- ROE
- 10.1%
- ROCE
- 12.3%
- Dividend yield
- 0.02%
- 52w high / low
- 468/268
Metrics as of 9 Oct 2026. Not real time.
Track Gufic Biosciences Ltd
Cruxal reads every Gufic Biosciences Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Gufic Biosciences Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 17%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- 19%
- 10 Years
- 27%
- 5 Years
- 15%
- 3 Years
- 14%
- 1 Year
- 11%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- 13%
- Last Year
- 10%
Gufic Biosciences Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹261 cr, up 16.5% from ₹224 cr a year earlier. Net profit was ₹22 cr, up 69.2% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 204 | 208 | 205 | 224 | 237 | 231 | 252 | 261 |
| Expenses | 166 | 174 | 179 | 190 | 199 | 198 | 205 | 214 |
| Operating profit | 39 | 34 | 26 | 33 | 38 | 33 | 47 | 47 |
| OPM % | 19% | 16% | 13% | 15% | 16% | 14% | 19% | 18% |
| Other income | 0 | 2 | 0 | 1 | 2 | 1 | -1 | 0 |
| Interest | 5 | 5 | 8 | 9 | 10 | 8 | 9 | 9 |
| Depreciation | 4 | 5 | 8 | 8 | 8 | 8 | 8 | 8 |
| Profit before tax | 29 | 26 | 11 | 17 | 23 | 18 | 29 | 30 |
| Tax % | 26% | 26% | 27% | 24% | 26% | 30% | 24% | 26% |
| Net profit | 22 | 19 | 8 | 13 | 17 | 12 | 22 | 22 |
| EPS (₹) | 2.17 | 1.93 | 0.77 | 1.30 | 1.68 | 1.24 | 2.18 | 2.22 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Gufic Biosciences Ltd annual results
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 807 | 820 | 944 | 981 |
| Operating profit | 150 | 136 | 151 | 165 |
| OPM % | 19% | 17% | 16% | 17% |
| Net profit | 86 | 70 | 64 | 73 |
| EPS (₹) | 8.59 | 6.95 | 6.40 | 7.32 |
TTM is the trailing twelve months to the most recent quarter.
Gufic Biosciences Ltd balance sheet
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 10 | 10 | 10 |
| Reserves | 523 | 591 | 655 |
| Borrowings | 333 | 336 | 405 |
| Other liabilities | 227 | 232 | 273 |
| Total liabilities | 1,093 | 1,169 | 1,342 |
| Fixed assets | 159 | 506 | 491 |
| CWIP | 307 | 22 | 22 |
| Investments | 2 | 2 | 2 |
| Other assets | 625 | 640 | 827 |
| Total assets | 1,093 | 1,169 | 1,342 |
As reported by the company. Total assets equal total liabilities by construction.
Gufic Biosciences Ltd cash flow
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operations | -7 | 123 | 45 |
| Cash from investing | -102 | -71 | -31 |
| Cash from financing | 82 | -37 | 32 |
| Net cash flow | -27 | 15 | 46 |
| Free cash flow | -116 | 52 | 14 |
| CFO / operating profit | 13% | 107% | 38% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Gufic Biosciences Ltd operating ratios
| Per year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | — | 13% | 12% |
| Debtor days | 149 | 140 | 115 |
| Inventory days | 188 | 211 | 281 |
| Days payable | 156 | 155 | 172 |
| Cash conversion cycle | 181 | 197 | 224 |
| Working capital days | 97 | 93 | 80 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Gufic Biosciences Ltd shareholding pattern
Promoters held 72.50% at Jun 2026, broadly unchanged since Jun 2025. FIIs 0.47% and DIIs 3.67%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 72.51% | 72.51% | 72.51% | 72.51% | 72.50% | 72.50% | 72.50% | 72.50% |
| FIIs | 0.23% | 0.30% | 0.31% | 0.32% | 0.33% | 0.44% | 0.42% | 0.47% |
| DIIs | 2.51% | 2.99% | 3.39% | 3.38% | 3.66% | 3.74% | 3.83% | 3.67% |
| Public | 24.75% | 24.20% | 23.79% | 23.81% | 23.51% | 23.30% | 23.23% | 23.36% |
| No. of shareholders | 32,825 | 33,299 | 31,844 | 31,876 | 31,420 | 30,362 | 29,223 | 29,753 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Gufic Biosciences Ltd corporate filings
- Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended September 30, 2026 is attached herewithCompany Updatelow impact
- Gufic Biosciences Ltd files regulatory disclosure under SEBI Listing RegulationsCompany Updatelow impact
Cruxal's analysis: Gufic Biosciences Ltd, a small-cap company with a market cap of approximately 4,359…
Read the full analysis - Intimation of closure of Trading Window is attached herewithInsider Trading / SASTlow impact
- Gufic Biosciences Ltd discloses ESG rating intimationCompany Updatelow impact
Cruxal's analysis: Gufic Biosciences Ltd has submitted an intimation regarding its Environmental, Social…
Read the full analysis - Gufic Biosciences Ltd: Routine Regulatory Disclosure under SEBI Regulation 30Company Updatelow impact
Cruxal's analysis: Gufic Biosciences Ltd has filed a routine disclosure under Regulation 30 of the SEBI…
Read the full analysis - Gufic Biosciences Limited receives credit rating reaffirmation from CRISIL with enhanced bank facility limit of 516 croreCompany Updatelow impact
Cruxal's analysis: Gufic Biosciences Limited has announced that CRISIL Ratings has reaffirmed its long-term…
Read the full analysis - Gufic Biosciences Limited Announces Successful Conclusion of 42nd Annual General Meeting and Approval of Final DividendAGM/EGMlow impact
Cruxal's analysis: Gufic Biosciences Limited has successfully concluded its 42nd Annual General Meeting held…
Read the full analysis - Gufic Biosciences announces promotion and change in designation of senior management personnelCompany Updatelow impact
Cruxal's analysis: Gufic Biosciences has filed an intimation under Regulation 30 of SEBI (LODR) Regulations…
Read the full analysis - Gufic Biosciences Q1 FY27 Earnings Call Highlights: Revenue Growth to INR 260.8 Crore with Margin ExpansionCompany Updatehigh impact
Cruxal's analysis: Gufic Biosciences Limited reported a strong Q1 FY27 performance with revenue from…
Read the full analysis - Gufic Biosciences Ltd announces newspaper publication for physical share dematerialization windowCompany Updatelow impact
Cruxal's analysis: Gufic Biosciences has published a newspaper advertisement regarding a special window for…
Read the full analysis - Gufic Biosciences Limited uploads audio recording of earnings conference call for the quarter ended June 2026Company Updatelow impact
Cruxal's analysis: Gufic Biosciences Limited has formally uploaded the audio recording of its earnings…
Read the full analysis - Gufic Biosciences Limited reports unaudited financial results for the quarter ended June 30, 2026Company Updatelow impact
Cruxal's analysis: Gufic Biosciences Limited has released its unaudited standalone and consolidated…
Read the full analysis - Gufic Biosciences Q1 FY2027 Results: Revenue Growth to 260.8 crore with EBITDA Margin Expansion to 18.09%Company Updatehigh impact
Cruxal's analysis: Gufic Biosciences Limited reported a strong Q1 FY2027 performance with total revenue of…
Read the full analysis - Gufic Biosciences to expand international footprint with new subsidiary in the PhilippinesCompany Updatemedium impact
Cruxal's analysis: Gufic Biosciences Limited has announced the board's approval to incorporate a new…
Read the full analysis - Gufic Biosciences Reports Q1 FY27 Financial Results and Announces Strategic Expansion into the PhilippinesBoard Meetinghigh impact
Cruxal's analysis: Gufic Biosciences Limited reported standalone revenue of 260.82 crore for the quarter…
Read the full analysis - Gufic Biosciences Ltd announces 42nd Annual General Meeting and e-voting detailsCompany Updatelow impact
Cruxal's analysis: Gufic Biosciences Ltd has issued a newspaper advertisement regarding the notice of its…
Read the full analysis - Gufic Biosciences Ltd files Business Responsibility and Sustainability Report (BRSR) for FY 2025-26Otherslow impact
Cruxal's analysis: Gufic Biosciences has submitted its Business Responsibility and Sustainability Report…
Read the full analysis - Gufic Biosciences Ltd releases Annual Report for FY 2025-2026 and Notice of 42nd AGMOtherslow impact
Cruxal's analysis: Gufic Biosciences has filed its Annual Report for the financial year 2025-2026 along with…
Read the full analysis - Gufic Biosciences Limited Announces 42nd AGM, Final Dividend of 0.10 INR per share, and Re-appointment of Whole Time DirectorAGM/EGMlow impact
Cruxal's analysis: Gufic Biosciences Limited has scheduled its 42nd Annual General Meeting for September 4…
Read the full analysis - Gufic Biosciences Limited schedules Q1 FY27 earnings conference call for August 17, 2026Company Updatelow impact
Cruxal's analysis: Gufic Biosciences Limited has announced an earnings conference call to discuss its…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.